Compare McDonald's Corp (MCD) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McDonald's Corp vs Nuvalent Inc — how do they compare? McDonald's Corp trades at $264.12 (market cap $190.16B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: McDonald's Corp is far larger — about 19.4× Nuvalent Inc's market cap, and McDonald's Corp pays a 2.78% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| MCD | NUVL | |
|---|---|---|
Market Cap | $190.16B | $9.81B |
Volume | 2,230,036 | — |
Sector | Consumer Cyclical | Technology |
52-Week High | $341.06 | $123.96 |
52-Week Low | $264.54 | $72.16 |
Enterprise Value | $243.87B | $8.52B |
Dividend Yield | 2.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McDonald's (MCD) trades at $267.71, down 2.1% on the day, with a bearish technical signal driven by moving averages. The company reported steady revenue growth to $26.89 billion in 2025 and a net income margin of 31.62%, though Q2 2026 earnings are pending. Recent news highlights a new 'McDonald's NEXT' strategy focusing on automation and menu improvements to boost competitiveness.
The stock presents a buying opportunity with a consensus price target of $329, implying 23% upside, supported by strong analyst sentiment (58% buy ratings). Risks include inflationary pressures on franchisee margins and high long-term debt of $38.42 billion. Earnings execution and strategy rollout will be key for near-term performance.
Nuvalent (NUVL) trades at $123.96, unchanged on the day, with a bullish technical signal from moving averages but overbought oscillators. The company reported a net loss of $425.38 million for 2025 and negative cash flow from operations. Recent news is dominated by GSK's proposed acquisition of Nuvalent for $124 per share, announced in June 2026, which is under investigation by multiple law firms for fairness to shareholders.
The investment outlook is heavily influenced by the pending acquisition. While analyst consensus shows no sell ratings, the stock price is near the offer price, limiting upside. Key risks include the deal's completion and the company's ongoing losses. The primary opportunity is the acquisition premium, but fundamental challenges persist absent the deal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
